Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production

Autoimmunity

Volumn 41, Issue 5, 2008, Pages 363-371

  Zheng, Biao ^a   Switzer, Kirsten ^a   Marinova, Ekaterina ^a   Zhang, Jinwu ^a   Han, Shuhua ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Auto antibodies; Autoimmunity; Collogen induced arthritis; Copolymer I; Rheumatoid arthritis

Indexed keywords

AUTOANTIBODY; GLATIRAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DISEASE EXACERBATION; GERMINAL CENTER; IMMUNE RESPONSE; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COLLAGEN; GERMINAL CENTER; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MICE; MICE, INBRED DBA; PEPTIDES; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 45949098901     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930801931001     Document Type: Article

References (61)

1. Teitelbaum, D., Meshorer, M., Hirshfeld, T., Sela, M. and Arnon, R. (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol, 1, pp. 242-248.
2. Teitelbaum, D., Webb, C., Bree, M., Meshorer, A., Arnon, R. and Sela, M. (1974) Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol, 3, pp. 256-262.
3. Teitelbaum, D., Fridkis-Hareli, M., Arnon, R. and Sela, M. (1996) Copolymer 1 inhibits chronic relapsing allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP specific T cell responses. J Neuroimmunol, 64, pp. 209-217.
4. Aharoni, R., Teitelbaum, D., Sela, M. and Arnon, R. (1998) Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol, 91, pp. 135-146.
5. Arnon, R. (1996) The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis-personal reflections. Immunol Lett, 50, pp. 1-15.
6. Bornstein, MB, Miller, A., Slagle, S., Weitzman, M., Crystal, H., Drexler, E., Keilson, M., Merriam, A., Wassertheil-Smoller, S. Spada, V. et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med, 317, pp. 408-414.
7. Bornstein, MB, Miller, A., Slagle, S., Weitzman, M., Drexler, E., Keilson, M., Spada, V., Weiss, W., Appel, S. Rolak, L. et al. (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology, 4, pp. 533-539.
8. Stark, Y. (1994) Expanded clinical trials of treatments for multiple sclerosis: Copolymer 1 (COP-1) treatment investigational new drug (IND) program. Ann Neurol, 36, pp. 114-115.
9. Miller, A., Shapiro, S., Gershtein, R., Kinarty, A., Rawashdeh, H., Honigman, S. and Lahat, N. (1998) Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol, 92, pp. 113-121.
10. Zhang, M., Chan, C., Vistica, B., Hung, V., Wiggert, B. and Gery, I. (2000) Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol, 103, pp. 189-194.
11. Angelov, DN, Waibel, S., Guntinas-Lichius, O., Lenzen, M., Neiss, WF, Tomov, TL, Yoles, E., Kipnis, J., Schori, H. Reuter, A. et al. (2003) Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for ALS. Proc Natl Acad Sci USA, 100, pp. 4790-4795.
12. Arnon, R. and Sela, M. (2003) Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit, 16, pp. 412-421.
13. Schlegel, PG, Aharoni, R., Chen, Y., Chen, J., Teitelbaum, D., Arnon, R., Sela, M. and Chao, NJ (1996) A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T cell proliferative responses to major and minor histo-compatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Natl Acad Sci USA, 93, pp. 5061-5066.
14. Aharoni, R., Schlege, lPG, Teitelbaum, D., Roikhel-Karpov, O., Chen, Y., Arnon, R., Sela, M. and Chao, NJ (1997) Studies on the mechanism and specificity of the synthetic copolymer GLAT on graft-versus-host disease. Immunol Lett, 58, pp. 79-87.
15. Aharoni, R., Teitelbaum, D., Arnon, R. and Sela, M. (2001) Copolymer 1 inhibits manifestations of graft rejection. Transplantation, 72, pp. 598-605.
16. Racke, MK, Martin, R., McFarland, H. and Fritz, RB (1992) Copolymer-1-induced inhibition of antigen-specific T cell activation: Interference with antigen presentation. J Neuroimmunol, 37, pp. 75-84.
17. Fridkis-Hareli, M., Teitelbaum, D., Gurevich, E., Pecht, I., Brautbar, C., Kwon, OJ, Brenner, T., Arnon, R. and Sela, M. (1994) Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatability complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc Natl Acad Sci USA, 91, pp. 4872-4876.
18. Fridkis-Hareli, M., Rosloniec, EF, Fugger, L. and Strominger, JL (1998) Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc Natl Acad Sci USA, 95, pp. 12528-12531.
19. Fridkis-Hareli, M., Neveu, JM, Robinson, RA, Lane, WS, Gauthier, L., Wucherpfennig, KW, Sela, M. and Strominger, JL (1999) Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol, 162, pp. 4697-4704.
20. Teitelbaum, D., Aharon, iR, Fridkis-Hareli, M., Arnon, R. and Sela, M. (1999) Development of copolymer 1 (Copaxone) as a specific drug against multiple sclerosis. The decade of autoimmunity, pp. 191-196. Elsevier Science, Amsterdam
21. Lando, Z., Teitelbaum, D. and Arnon, R. (1979) Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol, 132, pp. 2156-2160.
22. Aharoni, R., Teitelbaum, D., Sela, M. and Arnon, R. (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA, 94, pp. 10821-10826.
23. Aharoni, R., Teitelbaum, D. and Arnon, R. (1993) T-suppressor hybridomas and IL-2 dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur J Immunol, 23, pp. 17-25.
24. Vollmer, T. (1998) Safety and tolerability of glatiramer acetate for injection (formerly known as copolymer 1) in the treatment of multiple sclerosis patients previously treated with interferon β-1b. Ann Neurol, 44, p. 505.
25. Aharoni, R., Teitelbaum, D., Leitner, O., Meshorer, A., Sela, M. and Arnon, R. (2000) Specific Th2 cells accumulate in the central nervous system of mice protected against EAE by copolymer. Proc Natl Acad Sci USA, 97, pp. 11472-11477.
26. Aharoni, R., Meshorer, A., Sela, M. and Arnon, R. (2002) Oral treatment of mice with copolymer 1 (glatiramer acetate) results in accumulation of specific Th2 cells in the central nervous system. J Neuroimmunol, 126, pp. 58-68.
27. Weiner, HL (1999) Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. Proc Natl Acad Sci USA, 96, pp. 3333-3335.
28. Hong, J., Li, N., Zhang, X., Zheng, B. and Zhang, JZ (2005) Induction of CD4+ CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA, 102, pp. 6449-6454.
29. Trentham, D. (1982) Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum, 25, pp. 911-916.
30. Holmdahl, R., Andersson, M., Goldschmidt, TJ, Gustafsson, K., Jansson, L. and Mo, JA (1932) Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev, 118, p. 32.
31. Nabozny, GH and David, CS (1994) The immunogenetic basis of collagen induced arthritis in mice: An experimental model for the rational design of immuno-modulatory treatments of rheumatoid arthritis. Adv Exp Med Biol, 347, pp. 55-63.
32. Myers, LK, Rosloniec, EF, Cremer, MA and Kang, AH (1997) Collagen-induced arthritis, an animal model of autoimmunity. Life Sci, 61, pp. 1861-1878.
33. Stuart, JM, Cremer, MA, Townes, AA and Kang, AH (1982) Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med, 155, pp. 1-16.
34. Wooley, PH, Luthra, HS, Krco, CJ, Stuart, JM and David, CS (1984) Type II collagen-induced arthritis in mice. 1984. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen. Arthritis Rheum, 27, pp. 1010-1017.
35. Trentham, DE, Dynesius, RA and David, JR (1978) Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Invest, 62, pp. 359-366.
36. Holmdahl, R., Klareskog, L., Rubin, K., Larsson, E. and Wigzell, H. (1985) T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol, 22, pp. 295-306.
37. Griffiths, MM, Eichwald, EJ, Martin, JH, Smith, CB and DeWitt, CW (1981) Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats. Arthritis Rheum, 24, pp. 781-789.
38. Wooley, PH, Luthra, HS, Krco, CJ, Stuart, JM and David, CS (1981) Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med, 154, pp. 688-700.
39. Banerjee, S., Haqqi, TM, Luthra, HS, Stuart, JM and David, CS (1988) Possible role of V beta T cell receptor genes in susceptibility to collagen-induced arthritis in mice. J Exp Med, 167, pp. 832-839.
40. Grabbe, S. and Schwarz, T. (1998) Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today, 19, pp. 37-44.
41. Mauri, C., Williams, RO, Walmsley, M. and Feldmann, M. (1996) Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol, 26, pp. 1511-1518.
42. Doncarli, A., Stasiuk, L., Fournier, C. and Abehsira-Amar, O. (1997) Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis. Eur J Immunol, 27, pp. 1451-1458.
43. Joosten, LA, Lubberts, E., Durez, P., Helse, MM, Jacobs, MJ, Goldman, M. and van den Berg, WB (1997) Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Arthritis Rheum, 40, pp. 249-260.
44. McIntyre, KW, Shuster, DJ, Gillooly, KM, Warrier, RR, Connaughton, SE, Hall, LB, Arp, LH, Gately, MK and Magram, J. (1996) Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur J Immunol, 26, pp. 2933-2938.
45. Tada, Y., Ho, A., Matsuyama, T. and Mak, TW (1997) Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J Exp Med, 185, pp. 231-238.
46. Koenders, MI, Joosten, LA and van den Berg, WB (2006) Potential new targets in arthritis therapy: Interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis, 65, pp. 29-33.
47. Asquith, DL and McInnes, IB (2007) Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol, 19, pp. 246-251.
48. Brennan, F. and Beech, J. (2007) Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol, 19, pp. 296-301.
49. Wooley, PH, Luthra, HS, Krco, CJ, Stuart, JM and David, CS (1984) Type II collagen-induced arthritis in mice. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen. Arthritis Rheum, 27, pp. 1010-1017.
50. Hirofuji, T., Hori, H., Nagai, Y., Saisho, K., Sumiyoshi, A. and Koga, T. (1985) Characterization of monoclonal antibody specific for human type II collagen: Possible implication in collagen-induced arthritis. Clin Exp Immunol, 62, pp. 159-166.
51. Terato, K., Hasty, KA, Reife, RA, Cremer, MA, Kang, AH and Stuart, JM (1992) Induction of arthritis with monoclonal antibodies to collagen. J Immunol, 148, pp. 2103-2108.
52. Holmdahl, R., Rubin, K., Klareskog, L., Larsson, E. and Wigzell, H. (1986) Characterization of the Ab response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum, 29, pp. 400-410.
53. Kelsoe, G. (1995) In situ studies of the germinal center reaction. Adv Immunol, 60, pp. 267-288.
54. MacLennan, ICM (1994) Germinal centers. Annu Rev Immunol, 12, pp. 117-139.
55. Liu, YJ and Arpin, C. (1997) Germinal center development. Immunol Rev, 156, pp. 111-126.
56. Johansson, AC, Hansson, AS, Nandakumar, KA, Backlund, J. and Holmdahl, R. (2001) IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol, 167, pp. 3505-3512.
57. Hirofuji, T., Kakimoto, K., Hori, H., Nagai, Y., Saisho, K., Sumiyoshi, A. and Koga, T. (1985) Characterization of monoclonal antibody specific for human type II collagen: Possible implicationin collagen-induced arthritis. Clin Exp Immunol, 62, pp. 159-166.
58. Terato, K., Hasty, KA, Reife, RA, Cremer, MA, Kang, AH and Stuart, JM (1992) Induction of arthritis with monoclonal antibodies to collagen. J Immunol, 148, pp. 2103-2108.
59. Holmdahl, R., Jansson, L., Larsson, E., Rubin, K. and Klareskog, K. (1986) Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum, 29, pp. 106-113.
60. Han, S., Cao, S., Bheekha-Escura, R. and Zheng, B. (2001) Germinal center reaction in the joints of mice with collagen-induced arthritis. Arthritis Rheum, 44, pp. 1438-1443.
61. Wolfowicz, CB, Sakorafas, P., Rothstein, TL and Marshak-Rothestein, A. (1988) Oligoclonality of rheumatoid factors arising spontaneously in lpr/ lpr mice. Clin Immunol Immunopath, 46, pp. 382-395.